Related Content
Search Google Scholar for:
|
|
Science 7 June 1985:
Vol. 228. no. 4704, pp. 1195 - 1199
DOI: 10.1126/science.2408336
|
|
Articles
Science, Vol 228, Issue 4704, 1195-1199
Copyright © 1985 by American Association for the Advancement of Science
Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen
DR Milich,
GB Thornton,
AR Neurath,
SB Kent,
ML Michel,
P Tiollais,
and
FV Chisari
The 55 codons upstream of the gene sequence encoding the hepatitis B surface antigen (HBsAg) are called the pre-S(2) region. It has been proposed that polypeptides of high molecular weight that contain the pre-S(2) region should be included in future hepatitis B virus (HBV) vaccines. The pre-S(2) region and the S gene product [25 kilodalton (kD)] together compose a polypeptide of high molecular weight (33 kD). As an initial attempt to determine the relevance of the 33-kD polypeptide to development of an HBV vaccine, the murine immune response to pre-S(2)-encoded determinants as compared to S-encoded determinants on the same polypeptide was examined. The results indicate (i) the pre-S(2) region is significantly more immunogenic than the S region of HBsAg, (ii) the 26 amino acid residues at the NH2-terminus of the 33-kD polypeptide represent a dominant antibody binding site on the pre-S(2) region, (iii) the immune response to the pre-S(2) region is regulated by H-2-linked genes distinct from those that regulate the response to the S region, and (iv) immunization of an S region nonresponder strain with HBV envelope particles that contain both the pre-S(2) and S regions can circumvent nonresponsiveness to the S region.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Expression of the Human Hepatitis B Virus Large Surface Antigen Gene in Transgenic Tomato Plants.
- X.-M. Lou, Q.-H. Yao, Z. Zhang, R.-H. Peng, A.-S. Xiong, and H.-K. Wang (2007)
Clin. Vaccine Immunol.
14, 464-469
| Abstract »
| Full Text »
| PDF »
- High Prevalence of Hepatitis B Virus Pre-S Mutant in Countries Where It Is Endemic and Its Relationship with Genotype and Chronicity.
- T. T.-T. Huy, H. Ushijima, K. M. Win, P. Luengrojanakul, P. K. Shrestha, Z.-H. Zhong, A. V. Smirnov, T. C. Taltavull, T. Sata, and K. Abe (2003)
J. Clin. Microbiol.
41, 5449-5455
| Abstract »
| Full Text »
| PDF »
- Immune Responses to Hepatitis B Vaccine With and Without the Pre-S2 Antigen in Children With Type 1 Diabetes.
- M. Mancuso, M. Caruso-Nicoletti, S. Bianca, G. Granata, G. Li Volti, and S. Li Volti (2001)
Diabetes Care
24, 1841-1842
| Full Text »
| PDF »
- Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype.
- D. Sobotta, I. Sominskaya, J. Jansons, H. Meisel, S. Schmitt, K.-H. Heermann, G. Kaluza, P. Pumpens, and W. H. Gerlich (2000)
J. Gen. Virol.
81, 369-378
| Abstract »
| Full Text »
- Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus DNA Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes.
- Y.-H. Chow, B.-L. Chiang, Y.-L. Lee, W.-K. Chi, W.-C. Lin, Y.-T. Chen, and M.-H. Tao (1998)
J. Immunol.
160, 1320-1329
| Abstract »
| Full Text »
| PDF »
- Intradermal vs Intramuscular Hepatitis B Vaccinations-Reply.
- J. A. Clarke and F. B. Hollinger (1990)
JAMA
264, 182
| Abstract »
| PDF »
- Lack of Response to Recombinant Hepatitis B Vaccine in Nonresponders to the Plasma Vaccine.
- J. Y. Weissman, M. M. Tsuchiyose, M. J. Tong, R. Co, K. Chin, and R. B. Ettenger (1988)
JAMA
260, 1734-1738
| Abstract »
| PDF »
- Hepatitis B Vaccines--to Switch or Not to Switch.
- F. B. Hollinger (1987)
JAMA
257, 2634-2636
| Abstract »
| PDF »
- A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles.
- F Delpeyroux, N Chenciner, A Lim, Y Malpiece, B Blondel, R Crainic, S van der Werf, and R. Streeck (1986)
Science
233, 472-475
| Abstract »
| PDF »
|
|
